The exciting future of antifungal therapy

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 19, Issue 12, 2000, Pages 897-914

  Neely, M N ^a   Ghannoum, M A ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; CIPROFLOXACIN; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; FUNGUS VACCINE; ITRACONAZOLE; MC 510027; MICAFUNGIN; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; RIFAMPICIN; TACROLIMUS; UNCLASSIFIED DRUG; VORICONAZOLE;

CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; HUMAN; IMMUNOMODULATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; PRIORITY JOURNAL; REVIEW; VACCINATION;

ANTIFUNGAL AGENTS; FUNGAL VACCINES; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES;

EID: 0034468901     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960000395     Document Type: Review

References (208)

1. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998
2. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
3. Antifungal agents: Chemotherapeutic targets and immunologic strategies
4. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development
5. Introduction to antifungal drugs
6. Practice guidelines for the management of cryptococcal disease
7. Practice guidelines for diseases caused by Aspergillus
8. Practice guidelines for the management of patients with histoplasmosis
9. Practice guidelines for the management of patients with sporotrichosis
10. Practice guidelines for the management of patients with blastomycosis
11. Practice guidelines for the treatment of candidiasis
12. Practice guidelines for the treatment of fungal infections
13. Practice guideline for the treatment of coccidioidomycosis
14. Antifungal susceptibility testing
15. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections
16. Susceptibility testing of fungi: Current status of correlation of in vitro data with clinical outcome
17. Amphotericin B-resistant yeast infection in severely immunocompromised patients
18. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models
19. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species
20. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei
21. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species
22. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection
23. Damage to yeast cells of Cryptococcus neoformans by voriconazole and fluconazole: A culture and microscopic study
24. Anticryptococcal activity of voriconazole against Cryptococcus neoformans var. gatti vs. var. neoformans: Comparison with fluconazole and effect of human serum
25. In vitro activity of voriconazole against Candida species
26. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates
27. Voriconazole against fluconazole-susceptible and -resistant Candida isolates: In-vitro efficacy compared with that of itraconazole and ketoconazole
28. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp
29. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa
30. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients
31. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain
32. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole
33. Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans
34. Activity of voriconazole: Post-antifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes
35. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin
36. In vitro evaluation of voriconazole against some clinically important fungi
37. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens
38. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
39. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species
40. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus
41. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B
42. In vitro activity of voriconazole against selected fungi
43. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications
44. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin
45. In vitro activity of voriconazole and SCH 56592 against clinical isolates of Coccidioides immitis in various saprobic stages
46. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi
47. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi
48. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates
49. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole
50. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B
51. UK-109,496, A novel, wide-spectrum triazole derivative for the treatment of fungal infections: Activity in systemic candidasis models and early clinical efficacy in oropharyngeal candidiasis
52. Efficacy of voriconazole in the treatment of hematogenously disseminated Candida glabrata in a neutropenic guinea pig model
53. Efficacy of voriconazole in a guinea pig model of systemic C. albicans infection caused by isolates with elevated fluconazole MICs
54. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Antifungal activity in experimental infections with Cryptococcus
55. The efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis
56. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Antifungal activity in experimental infections with Aspergillus
57. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis
58. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model
59. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs
60. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Clinical efficacy in acute invasive aspergillosis
61. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Clinical efficacy in chronic invasive aspergillosis
62. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia
63. Microgranulomatous aspergillosis in a patient with chronic granulomatous disease: Cure with voriconazole
64. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease
65. Use of voriconazole in treatment of Scedosporium apiospermum infection: Case report
66. A double-blind, randomized, multi-center trial of voriconazole vs. fluconazole for the treatment of esophageal candidiasis in immunocompromised adults
67. Voriconazole vs. liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients: A randomized, international, multicenter trial
68. Efficacy and safety of voriconazole in the treatment of invasive fungal infection in children
69. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Pharmacokinetics in man
70. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Disposition in man
71. Voriconazole does not affect the pharmacokinetics of digoxin
72. The pharmacokinetics of voriconazole and its effect on prednisolone disposition
73. Effect of omeprazole on the pharmacokinetics of voriconazole
74. Effects of rifampicin and rifabutin on the pharmacokinetics of voriconazole
75. Voriconazole potentiates warfarin-induced prolongation of prothrombin time
76. The effect of voriconazole on the pharmacokinetics of cyclosporin
77. Drug interactions between voriconazole and phenytoin
78. No significant pharmacokinetic interactions between voriconazole and indinavir
79. Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp
80. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae
81. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents
82. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens
83. In vitro susceptibilities of environmental Cryptococcus neoformans variety neoformans isolates to six antifungal agents including SCH56692
84. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp
85. In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi
86. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis
87. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus
88. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: In vitro and in vivo studies
89. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniasis
90. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice
91. Efficacy of SCH 56592 in a murine model of systemic coccidioidomycosis
92. Treatment of murine fusariosis with SCH 56592
93. Efficacy of SCH56592 in treatment and prevention of invasive pulmonary aspergillosis in persistently neutropenic rabbits
94. Posaconazole equivalent to fluconazole in the treatment of oral pharyngeal candidiasis
95. Posaconazole compared to fluconazole for oral candidiasis in HIV-positive patients
96. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections refractory to or intolerant to standard therapy
97. International surveillance of bloodstream infections due to Candida species in the European SENTRY Program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents
98. In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America
99. In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole
100. In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
101. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis
102. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum
103. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B
104. Ravuconazole single ascending oral dose study in healthy subjects
105. In vitro activity of L-743,872 against putatively amphotericin B and fluconazole resistant Candida isolates
106. Antifungal peptides: Novel therapeutic compounds against emerging pathogens
107. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors
108. LY303366: A noncompetitive inhibitor of (1,3)-b-D-glucan synthases from Candida albicans and Aspergillus fumigatus
109. LY303366 - A new semisynthetic lipopeptide antifungal agent related to echinocandin B. Synthetic and structure activity studies
110. Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives
111. L-743,872, a novel antifungal lipopeptide: Synthesis and structure activity relationships of new aza-substituted pneumocandins
112. Efficacy of FK463, a novel water-soluble echinocandin-like lipopeptide in murine models of disseminated candidiasis
113. Efficacy of FK463, a novel water-soluble echinocandin-like lipopeptide, in murine models of pulmonary aspergillosis
114. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in SCID mice
115. A multicenter study to determine the minimal effective dose of FK463 for the treatment of esophageal candidiasis in HIV-positive patients
116. Maximum tolerated dose and pharmacokinetics of FK463 in combination with fluconazole for the prophylaxis of fungal infections in adult bone marrow transplant or peripheral stem cell transplant patients
117. Phase I study of FK463, a new antifungal agent, in healthy adult male volunteers
118. Treatment of murine disseminated candidiasis with L-743,872
119. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872
120. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii
121. Treatment of histoplasmosis with MK-991 (L-743,872)
122. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)
123. Single- and multiple-dose pharmacokinetics of the antifungal agent MK-0991 in man
124. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B (AMB), AMB lipid formulations, or azoles
125. Elongation factor 2 as a novel target for selective inhibition of fungal protein synthesis
126. Sordarins: A new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts
127. Pradimicins: A novel class of broad-spectrum antifungal compounds
128. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole
129. New approaches to antifungal chemotherapy
130. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis
131. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS
132. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients
133. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses
134. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis
135. Candida meningitis in two children with severe combined immunodeficiency
136. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS
137. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis
138. Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis
139. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans
140. In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans
141. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B
142. In vitro activity of voriconazole in combination with amphotericin B or 5 flucytosine against clinical fluconazole-resistant Candida albicans
143. In vitro interaction between amphotericin B and azoles in Candida albicans
144. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis
145. Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum
146. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models
147. Combined effect of amphotericin B and rifampin on Candida species
148. Synergistic action of amphotericin B and rifampin against Rhizopus species
149. In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp
150. Combined in vitro effect of amphotericin B and rifampin on Cryptococcus neoformans
151. Combination antifungal chemotherapy for experimental disseminated candidiasis: Lack of correlation between in vitro and in vivo observations with amphotericin B and rifampin
152. Interaction of rifampin with other antifungal agents in experimental murine candidiasis
153. Combination therapy in a model of pulmonary aspergillosis
154. Antifungal and surgical treatment of invasive aspergillosis: Review of 2,121 published cases
155. Rifampin-fluconazole interaction in critically ill patients
156. Induction of fluconazole metabolism by rifampin: In vivo study in humans
157. Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs
158. Combination antifungal therapy with FK463 plus amphotericin B in treatment of experimental pulmonary aspergillosis
159. Synergistic effects of combination FK463 with amphotericin B: Enhanced efficacy in murine model of invasive pulmonary aspergillosis
160. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein
161. Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans
162. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance
163. Induced expression of the Candida albicans multidrug resistance gene CDR1 in response to fluconazole and other antifungals
164. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus
165. Impact of MC-510,027, a fungal efflux pump inhibitor, on the susceptibility of clinical isolates of Candida spp. to antifungal agents
166. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections
167. Itraconazole in cyclodextrin solution
168. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial
169. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double-blind, placebo-controlled study
170. Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans
171. In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus
172. Are cochleates the new lipid-based carrier for oral drug delivery?
173. Oral administration of amphotericin B with a new AmB-cochleate formulation: Tissue distribution after single and multiple oral doses
174. Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin B, gamma interferon and GM-CSF
175. Evaluation of antibody-bearing liposomal amphotericin B in the treatment of systemic candidiasis in a neutropenic murine model
176. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: Study during murine cryptococcosis and mechanisms of action
177. Treatment of a murine model of systemic candidiasis with liposomal amphotericin B beating antibody to Candida albicans
178. High-dose therapy with fluconazole > or = 800 mg day-1
179. Cytokines and mycoses
180. Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: An ongoing dilemma or an unnecessary dispute?
181. Type 1 and type 2 cytokines: From basic science to fungal infections
182. Immunity to fungi: Editorial overview
183. The role of immunoreconstitution in the management of refractory opportunistic fungal infections
184. The potential role of cytokine therapy for fungal infections in patients with cancer: Is recovery from neutropenia all that is needed?
185. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor
186. Granulocyte colony stimulating factor (GCSF) and azole antifungal therapy in murine aspergillosis: Surprises
187. 1997 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
188. Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
189. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections
190. Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection
191. Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia
192. Fungal infections in bone marrow transplant patients
193. Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients
194. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: Results of a randomized, multicenter, controlled trial
195. Experimentally induced immunity in the mycoses
196. Prospects for the development of fungal vaccines
197. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B
198. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis
199. Antibody response that protects against disseminated candidiasis
200. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis
201. Potential role of phospholipases in virulence and fungal pathogenesis
202. The role of alpha-toxin of Clostridium perfringens in experimental gas gangrene in guinea pigs
203. New systematically active antimycotics from the beta-blocker category
204. Effects of adjuvant-augmented germling vaccines in turkey pours challenged with Aspergillus fumigatus
205. Acquired immunity in experimental murine aspergillosis is mediated by macrophages
206. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model